We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cellzome AG and Graffinity announced today that they will receive €2.2 million --€1.1 million each -- from the German Ministry of Research and Education for the discovery of novel treatments for disorders of the immune system.
SOLVAY PHARMACEUTICALS announces today that Meiji Seika Kaisha Ltd. (Tokyo) and Solvay Seiyaku K. K. (Tokyo) obtained approval of additional indication of Social Anxiety Disorder (Social Phobia) from Japan's Ministry of Health, Labour, and Welfare on fluvoxamine maleate (DEPROMEL/ Meiji Seika, LUVOX/ Solvay Seiyaku) on October 11.
LAM Pharmaceutical, Corp. (OTC BB: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it granted its Latin American distribution partner, aQva Pharmaceuticals, exclusive distribution
rights for Brazil and Argentina.
Allos Therapeutics, Inc. (Nasdaq: ALTH -- News) today announced that it has withdrawn its European Marketing Authorization Application (MAA) for its investigational radiation sensitizer REVAPROXYN(TM) (efaproxiral, EFAPROXYN(TM) in the United States) for use as an adjunct to whole brain radiation therapy (WBRT) for the treatment of patients with brain metastases originating from breast cancer.
Trigen Holdings AG, the cardiovascular drug discovery and development company, today announced the completion of a 26.5m euro (US$31.9m) financing round with an international syndicate of new and existing investors.
Eisai Co., Ltd. (President & CEO: Haruo Naito) and TorreyPines Therapeutics, Inc. (President & CEO: Neil Kurtz, M.D.) today jointly announced the signing of a new research agreement that focuses on the discovery of genes responsible for late onset Alzheimer's disease.